News item

Enzyre awarded with €2M grant

Enzyre’s platform technology requires just a small volume of blood and is able to measure up to twelve reactions simultaneously with high sensitivity and specificity, that can be carried out at home, on the road or in a critical care setting, without any laboratory infrastructure. This has the potential for better disease management and to improve the lives of patients living with chronic conditions whilst reducing healthcare costs.


Enzyre, a spin-out from Radboud University Medical Center in The Netherlands, was set up by Guido Maertens and Waander van Heerde, to develop innovative point of care (POC) devices to measure biomarkers in complex solutions. POC diagnostic tools are crucial for cost reduction and offer the flexibility to allow disease management to move to personalized medicine in the home or critical care setting. Enzyre’s POC device aims to revolutionize the understanding and diagnosis of multiple
thrombotic and hemostatic disorders by providing a real-time picture of a patient’s blood coagulation status. The total market size for hemophilia is estimated at €12B per year. The €2M EFRO grant and the seed financing will enable Enzyre to further develop its Hemophilia Biochip and bring its first product
to market.



They also announce the appointment of Dirk Pollet as Chief Executive Officer, who states: “I’m very pleased to join a great team with an outstanding technology that offers tremendous potential to allow patients and healthcare professionals to manage disease in real time. With the seed financing from existing shareholders and business angels, and the €2M EFRO grant, we are now able to accelerate the development and
commercialization of our unique POC device to market.


Read more about Enzyre.

Share this news

Share on facebook
Share on twitter
Share on linkedin

Fighting malaria is fighting poverty

Diseases that spread across the globe come and go, but malaria has been around for thousands of years. The number of people affected by the disease is on the rise and it hits lower-income countries the hardest. So how can we fight malaria, and what will it bring to the world if we manage to do so? Koen Dechering, CEO of TropIQ Health Sciences, explains why more needs to be done and how his company contributes to eradicating the disease once and for all.

Read More »

Subscribe the NTC Newsletter

We care about your privacy: Read more

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!